ING Group
BBNX icon

ING Group’s Beta Bionics BBNX Stock Holding History

ING Group’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.74M Buy
+250,000
New +$4.49M 0.03% 328

Other funds holding BBNX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

ING Group's BBNX Position: Q3 2026 in Review

ING Group opened a new position in Beta Bionics (BBNX) in Q3 2026: 250,000 shares worth $4.74M. The stake represents 0.03% of the portfolio and ranks #328 among its holdings.

62 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.

  • ING Group held 250,000 shares of Beta Bionics worth $4.74M as of Q3 2026.
  • Beta Bionics was a new ING Group position in Q3 2026.
  • Beta Bionics made up 0.03% of ING Group's portfolio in Q3 2026, its #328 holding.
  • 62 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.

Based on ING Group's 13F filing for Q3 2026, filed 10 Nov 2026.